In-office Assessment of Voiding Function Following Botox Injection for Overactive Bladder
Completed
Conditions studied: Overactive Bladder
In brief
The purpose of this study is to describe the rates of elevated post void residual (PVR) (defined as \>200mL) in Cincinnati Urogynecology Associates patients following Botox injection, as well as to document how many patients required treatment with clean intermittent self-catheterization (CISC).
Key facts
- Study ID
- NCT04155593
- Run by
- TriHealth Inc.
- People needed
- 135
- Starts
- 2019-11-08
- Expected to finish
- 2020-07-15
- Last updated by the study team
- 2020-09-02
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- OnabotulinumtoxinA injections in the bladder for overactive bladder
- Completed a post injection appointment at which time PVR was collected (approximately 10 to 28 days following Botox injection)
- Age >18
- English speaking
You may not qualify if…
- OnabotulinumtoxinA injection for any other cause than overactive bladder
- Patients requiring self-catheterization at baseline
- Failure to complete a postoperative appointment within 4 weeks of Botox injection
Where it is running
- Cincinnati Urogynecology Associates — Cincinnati, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.